APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Medulloblastoma Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Medulloblastoma Drug Industry Research Report 2026

Report ID 174011600522 December 2025122 pages

Choose your research edition.

Industry ResearchMedulloblastoma Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Medulloblastoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Medulloblastoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medulloblastoma Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Medulloblastoma Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Medulloblastoma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Medulloblastoma Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Medulloblastoma Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Medulloblastoma Drug include DelMar Pharmaceuticals Inc, Ignyta Inc, IMPACT Therapeutics Inc, Lipocure Ltd, MacroGenics Inc, NewLink Genetics Corp, Novogen Ltd, Ono Pharmaceutical Co Ltd and Progenics Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Medulloblastoma Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Medulloblastoma Drug Market by Company

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Lipocure Ltd

MacroGenics Inc

NewLink Genetics Corp

Novogen Ltd

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Stemline Therapeutics Inc

ThromboGenics NV

VBI Vaccines Inc

Bristol-Myers Squibb Company

Bayer AG

Medulloblastoma Drug Segment by Type

Ipilimumab

Dianhydrogalactitol

Indoximod

IMP-5471

Others

Medulloblastoma Drug Segment by Application

Hospital

Clinic

Others

Medulloblastoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medulloblastoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medulloblastoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medulloblastoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Medulloblastoma Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Medulloblastoma Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Medulloblastoma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Medulloblastoma Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Medulloblastoma Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Medulloblastoma Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Medulloblastoma Drug Revenue of Manufacturers (2021-2026) Table 9. Global Medulloblastoma Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Medulloblastoma Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Medulloblastoma Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Medulloblastoma Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Medulloblastoma Drug, Product Type & Application Table 14. Global Medulloblastoma Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Medulloblastoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. DelMar Pharmaceuticals Inc Company Information Table 19. DelMar Pharmaceuticals Inc Business Overview Table 20. DelMar Pharmaceuticals Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. DelMar Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio Table 22. DelMar Pharmaceuticals Inc Recent Developments Table 23. Ignyta Inc Company Information Table 24. Ignyta Inc Business Overview Table 25. Ignyta Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Ignyta Inc Medulloblastoma Drug Product Portfolio Table 27. Ignyta Inc Recent Developments Table 28. IMPACT Therapeutics Inc Company Information Table 29. IMPACT Therapeutics Inc Business Overview Table 30. IMPACT Therapeutics Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. IMPACT Therapeutics Inc Medulloblastoma Drug Product Portfolio Table 32. IMPACT Therapeutics Inc Recent Developments Table 33. Lipocure Ltd Company Information Table 34. Lipocure Ltd Business Overview Table 35. Lipocure Ltd Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Lipocure Ltd Medulloblastoma Drug Product Portfolio Table 37. Lipocure Ltd Recent Developments Table 38. MacroGenics Inc Company Information Table 39. MacroGenics Inc Business Overview Table 40. MacroGenics Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. MacroGenics Inc Medulloblastoma Drug Product Portfolio Table 42. MacroGenics Inc Recent Developments Table 43. NewLink Genetics Corp Company Information Table 44. NewLink Genetics Corp Business Overview Table 45. NewLink Genetics Corp Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. NewLink Genetics Corp Medulloblastoma Drug Product Portfolio Table 47. NewLink Genetics Corp Recent Developments Table 48. Novogen Ltd Company Information Table 49. Novogen Ltd Business Overview Table 50. Novogen Ltd Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Novogen Ltd Medulloblastoma Drug Product Portfolio Table 52. Novogen Ltd Recent Developments Table 53. Ono Pharmaceutical Co Ltd Company Information Table 54. Ono Pharmaceutical Co Ltd Business Overview Table 55. Ono Pharmaceutical Co Ltd Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Ono Pharmaceutical Co Ltd Medulloblastoma Drug Product Portfolio Table 57. Ono Pharmaceutical Co Ltd Recent Developments Table 58. Progenics Pharmaceuticals Inc Company Information Table 59. Progenics Pharmaceuticals Inc Business Overview Table 60. Progenics Pharmaceuticals Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Progenics Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio Table 62. Progenics Pharmaceuticals Inc Recent Developments Table 63. Stemline Therapeutics Inc Company Information Table 64. Stemline Therapeutics Inc Business Overview Table 65. Stemline Therapeutics Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Stemline Therapeutics Inc Medulloblastoma Drug Product Portfolio Table 67. Stemline Therapeutics Inc Recent Developments Table 68. ThromboGenics NV Company Information Table 69. ThromboGenics NV Business Overview Table 70. ThromboGenics NV Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. ThromboGenics NV Medulloblastoma Drug Product Portfolio Table 72. ThromboGenics NV Recent Developments Table 73. VBI Vaccines Inc Company Information Table 74. VBI Vaccines Inc Business Overview Table 75. VBI Vaccines Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. VBI Vaccines Inc Medulloblastoma Drug Product Portfolio Table 77. VBI Vaccines Inc Recent Developments Table 78. Bristol-Myers Squibb Company Company Information Table 79. Bristol-Myers Squibb Company Business Overview Table 80. Bristol-Myers Squibb Company Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Bristol-Myers Squibb Company Medulloblastoma Drug Product Portfolio Table 82. Bristol-Myers Squibb Company Recent Developments Table 83. Bayer AG Company Information Table 84. Bayer AG Business Overview Table 85. Bayer AG Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Bayer AG Medulloblastoma Drug Product Portfolio Table 87. Bayer AG Recent Developments Table 88. Global Medulloblastoma Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Medulloblastoma Drug Sales by Region (2021-2026) & (k units) Table 90. Global Medulloblastoma Drug Sales Market Share by Region (2021-2026) Table 91. Global Medulloblastoma Drug Sales by Region (2027-2032) & (k units) Table 92. Global Medulloblastoma Drug Sales Market Share by Region (2027-2032) Table 93. Global Medulloblastoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Medulloblastoma Drug Revenue Market Share by Region (2021-2026) Table 95. Global Medulloblastoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Medulloblastoma Drug Revenue Market Share by Region (2027-2032) Table 97. North America Medulloblastoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 99. North America Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 100. North America Medulloblastoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Medulloblastoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Medulloblastoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 104. Europe Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 105. Europe Medulloblastoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Medulloblastoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Medulloblastoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 109. Asia Pacific Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 110. Asia Pacific Medulloblastoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Medulloblastoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Medulloblastoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 114. South America Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 115. South America Medulloblastoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Medulloblastoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Medulloblastoma Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 119. Middle East and Africa Medulloblastoma Drug Sales by Country (2027-2032) & (k units) Table 120. Middle East and Africa Medulloblastoma Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Medulloblastoma Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 123. Global Medulloblastoma Drug Sales by Type (2027-2032) & (k units) Table 124. Global Medulloblastoma Drug Sales Market Share by Type (2021-2026) Table 125. Global Medulloblastoma Drug Sales Market Share by Type (2027-2032) Table 126. Global Medulloblastoma Drug Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Medulloblastoma Drug Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Medulloblastoma Drug Revenue Market Share by Type (2021-2026) Table 129. Global Medulloblastoma Drug Revenue Market Share by Type (2027-2032) Table 130. Global Medulloblastoma Drug Price by Type (2021-2026) & (US$/unit) Table 131. Global Medulloblastoma Drug Price by Type (2027-2032) & (US$/unit) Table 132. Global Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 133. Global Medulloblastoma Drug Sales by Application (2027-2032) & (k units) Table 134. Global Medulloblastoma Drug Sales Market Share by Application (2021-2026) Table 135. Global Medulloblastoma Drug Sales Market Share by Application (2027-2032) Table 136. Global Medulloblastoma Drug Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Medulloblastoma Drug Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Medulloblastoma Drug Revenue Market Share by Application (2021-2026) Table 139. Global Medulloblastoma Drug Revenue Market Share by Application (2027-2032) Table 140. Global Medulloblastoma Drug Price by Application (2021-2026) & (US$/unit) Table 141. Global Medulloblastoma Drug Price by Application (2027-2032) & (US$/unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Medulloblastoma Drug Distributors List Table 145. Medulloblastoma Drug Customers List Table 146. Medulloblastoma Drug Industry Trends Table 147. Medulloblastoma Drug Industry Drivers Table 148. Medulloblastoma Drug Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Medulloblastoma Drug Product Image Figure 5. Global Medulloblastoma Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Medulloblastoma Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Medulloblastoma Drug Sales (2021-2032) & (k units) Figure 8. Global Medulloblastoma Drug Average Price (US$/unit) & (2021-2032) Figure 9. Ipilimumab Product Image Figure 10. Dianhydrogalactitol Product Image Figure 11. Indoximod Product Image Figure 12. IMP-5471 Product Image Figure 13. Others Product Image Figure 14. Hospital Product Image Figure 15. Clinic Product Image Figure 16. Others Product Image Figure 17. Global Medulloblastoma Drug Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Medulloblastoma Drug, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Medulloblastoma Drug Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Medulloblastoma Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Medulloblastoma Drug Sales by Region in 2025 Figure 23. Global Medulloblastoma Drug Revenue by Region in 2025 Figure 24. North America Medulloblastoma Drug Market Size by Country in 2025 Figure 25. North America Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 26. North America Medulloblastoma Drug Revenue Market Share by Country (2021-2032) Figure 27. United States Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Medulloblastoma Drug Market Size by Country in 2025 Figure 31. Europe Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Medulloblastoma Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific Medulloblastoma Drug Market Size by Country in 2025 Figure 44. Asia Pacific Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific Medulloblastoma Drug Revenue Market Share by Country (2021-2032) Figure 46. China Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America Medulloblastoma Drug Market Size by Country in 2025 Figure 55. South America Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 56. South America Medulloblastoma Drug Revenue Market Share by Country (2021-2032) Figure 57. Brazil Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa Medulloblastoma Drug Market Size by Country in 2025 Figure 61. Middle East and Africa Medulloblastoma Drug Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa Medulloblastoma Drug Revenue Market Share by Country (2021-2032) Figure 63. Egypt Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries Medulloblastoma Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global Medulloblastoma Drug Sales Market Share by Type (2021-2032) Figure 69. Global Medulloblastoma Drug Revenue Market Share by Type (2021-2032) Figure 70. Global Medulloblastoma Drug Price (US$/unit) by Type (2021-2032) Figure 71. Global Medulloblastoma Drug Sales Market Share by Application (2021-2032) Figure 72. Global Medulloblastoma Drug Revenue Market Share by Application (2021-2032) Figure 73. Global Medulloblastoma Drug Price (US$/unit) by Application (2021-2032) Figure 74. Medulloblastoma Drug Value Chain Figure 75. Medulloblastoma Drug Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Medulloblastoma Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Ipilimumab
  • Dianhydrogalactitol
  • Indoximod
  • IMP-5471
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • DelMar Pharmaceuticals Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Lipocure Ltd
  • MacroGenics Inc
  • NewLink Genetics Corp
  • Novogen Ltd
  • Ono Pharmaceutical Co Ltd
  • Progenics Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • ThromboGenics NV
  • VBI Vaccines Inc
  • Bristol-Myers Squibb Company
  • Bayer AG

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Medulloblastoma Drug Market Size (2021-2032)
  4. 2.2.2 Global Medulloblastoma Drug Sales (2021-2032)
  5. 2.2.3 Global Medulloblastoma Drug Market Average Price (2021-2032)
  6. 2.3 Medulloblastoma Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Ipilimumab
  9. 2.3.3 Dianhydrogalactitol
  10. 2.3.4 Indoximod
  11. 2.3.5 IMP-5471
  12. 2.3.6 Others
  13. 2.4 Medulloblastoma Drug by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital
  16. 2.4.3 Clinic
  17. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Medulloblastoma Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Medulloblastoma Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Medulloblastoma Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Medulloblastoma Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Medulloblastoma Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Medulloblastoma Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Medulloblastoma Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Medulloblastoma Drug, Established Date
  9. 3.9 Global Medulloblastoma Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 DelMar Pharmaceuticals Inc
  2. 4.1.1 DelMar Pharmaceuticals Inc Company Information
  3. 4.1.2 DelMar Pharmaceuticals Inc Business Overview
  4. 4.1.3 DelMar Pharmaceuticals Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 DelMar Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio
  6. 4.1.5 DelMar Pharmaceuticals Inc Recent Developments
  7. 4.2 Ignyta Inc
  8. 4.2.1 Ignyta Inc Company Information
  9. 4.2.2 Ignyta Inc Business Overview
  10. 4.2.3 Ignyta Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Ignyta Inc Medulloblastoma Drug Product Portfolio
  12. 4.2.5 Ignyta Inc Recent Developments
  13. 4.3 IMPACT Therapeutics Inc
  14. 4.3.1 IMPACT Therapeutics Inc Company Information
  15. 4.3.2 IMPACT Therapeutics Inc Business Overview
  16. 4.3.3 IMPACT Therapeutics Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 IMPACT Therapeutics Inc Medulloblastoma Drug Product Portfolio
  18. 4.3.5 IMPACT Therapeutics Inc Recent Developments
  19. 4.4 Lipocure Ltd
  20. 4.4.1 Lipocure Ltd Company Information
  21. 4.4.2 Lipocure Ltd Business Overview
  22. 4.4.3 Lipocure Ltd Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Lipocure Ltd Medulloblastoma Drug Product Portfolio
  24. 4.4.5 Lipocure Ltd Recent Developments
  25. 4.5 MacroGenics Inc
  26. 4.5.1 MacroGenics Inc Company Information
  27. 4.5.2 MacroGenics Inc Business Overview
  28. 4.5.3 MacroGenics Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 MacroGenics Inc Medulloblastoma Drug Product Portfolio
  30. 4.5.5 MacroGenics Inc Recent Developments
  31. 4.6 NewLink Genetics Corp
  32. 4.6.1 NewLink Genetics Corp Company Information
  33. 4.6.2 NewLink Genetics Corp Business Overview
  34. 4.6.3 NewLink Genetics Corp Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 NewLink Genetics Corp Medulloblastoma Drug Product Portfolio
  36. 4.6.5 NewLink Genetics Corp Recent Developments
  37. 4.7 Novogen Ltd
  38. 4.7.1 Novogen Ltd Company Information
  39. 4.7.2 Novogen Ltd Business Overview
  40. 4.7.3 Novogen Ltd Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Novogen Ltd Medulloblastoma Drug Product Portfolio
  42. 4.7.5 Novogen Ltd Recent Developments
  43. 4.8 Ono Pharmaceutical Co Ltd
  44. 4.8.1 Ono Pharmaceutical Co Ltd Company Information
  45. 4.8.2 Ono Pharmaceutical Co Ltd Business Overview
  46. 4.8.3 Ono Pharmaceutical Co Ltd Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Ono Pharmaceutical Co Ltd Medulloblastoma Drug Product Portfolio
  48. 4.8.5 Ono Pharmaceutical Co Ltd Recent Developments
  49. 4.9 Progenics Pharmaceuticals Inc
  50. 4.9.1 Progenics Pharmaceuticals Inc Company Information
  51. 4.9.2 Progenics Pharmaceuticals Inc Business Overview
  52. 4.9.3 Progenics Pharmaceuticals Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Progenics Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio
  54. 4.9.5 Progenics Pharmaceuticals Inc Recent Developments
  55. 4.10 Stemline Therapeutics Inc
  56. 4.10.1 Stemline Therapeutics Inc Company Information
  57. 4.10.2 Stemline Therapeutics Inc Business Overview
  58. 4.10.3 Stemline Therapeutics Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Stemline Therapeutics Inc Medulloblastoma Drug Product Portfolio
  60. 4.10.5 Stemline Therapeutics Inc Recent Developments
  61. 4.11 ThromboGenics NV
  62. 4.11.1 ThromboGenics NV Company Information
  63. 4.11.2 ThromboGenics NV Business Overview
  64. 4.11.3 ThromboGenics NV Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 ThromboGenics NV Medulloblastoma Drug Product Portfolio
  66. 4.11.5 ThromboGenics NV Recent Developments
  67. 4.12 VBI Vaccines Inc
  68. 4.12.1 VBI Vaccines Inc Company Information
  69. 4.12.2 VBI Vaccines Inc Business Overview
  70. 4.12.3 VBI Vaccines Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 VBI Vaccines Inc Medulloblastoma Drug Product Portfolio
  72. 4.12.5 VBI Vaccines Inc Recent Developments
  73. 4.13 Bristol-Myers Squibb Company
  74. 4.13.1 Bristol-Myers Squibb Company Company Information
  75. 4.13.2 Bristol-Myers Squibb Company Business Overview
  76. 4.13.3 Bristol-Myers Squibb Company Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Bristol-Myers Squibb Company Medulloblastoma Drug Product Portfolio
  78. 4.13.5 Bristol-Myers Squibb Company Recent Developments
  79. 4.14 Bayer AG
  80. 4.14.1 Bayer AG Company Information
  81. 4.14.2 Bayer AG Business Overview
  82. 4.14.3 Bayer AG Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Bayer AG Medulloblastoma Drug Product Portfolio
  84. 4.14.5 Bayer AG Recent Developments
5 Global Medulloblastoma Drug Market Scenario by Region
  1. 5.1 Global Medulloblastoma Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Medulloblastoma Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Medulloblastoma Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Medulloblastoma Drug Sales by Region: 2027-2032
  5. 5.3 Global Medulloblastoma Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Medulloblastoma Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Medulloblastoma Drug Revenue by Region: 2027-2032
  8. 5.4 North America Medulloblastoma Drug Market Facts & Figures by Country
  9. 5.4.1 North America Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Medulloblastoma Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Medulloblastoma Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Medulloblastoma Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Medulloblastoma Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Medulloblastoma Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Medulloblastoma Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Medulloblastoma Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Medulloblastoma Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Medulloblastoma Drug Market Facts & Figures by Country
  41. 5.7.1 South America Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Medulloblastoma Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Medulloblastoma Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Medulloblastoma Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Medulloblastoma Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Medulloblastoma Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Medulloblastoma Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Medulloblastoma Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Medulloblastoma Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Medulloblastoma Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Medulloblastoma Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Medulloblastoma Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Medulloblastoma Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Medulloblastoma Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Medulloblastoma Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Medulloblastoma Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Medulloblastoma Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Medulloblastoma Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Medulloblastoma Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Medulloblastoma Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Medulloblastoma Drug Value Chain Analysis
  2. 8.1.1 Medulloblastoma Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Medulloblastoma Drug Production Mode & Process
  5. 8.2 Medulloblastoma Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Medulloblastoma Drug Distributors
  8. 8.2.3 Medulloblastoma Drug Customers
9 Global Medulloblastoma Drug Analyzing Market Dynamics
  1. 9.1 Medulloblastoma Drug Industry Trends
  2. 9.2 Medulloblastoma Drug Industry Drivers
  3. 9.3 Medulloblastoma Drug Industry Opportunities and Challenges
  4. 9.4 Medulloblastoma Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst